Citations

Clear

959 citation(s) found for "Service, F J".

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL
Paietta, Elisabeth , Wang, Victoria , Gu, Zhaohui , Buck, Georgina , Pei, Deqing, Levine, Ross L. , Cheng, Zhongshan , Pounds, Stanley , Racevskis, Janis, Bařinka, Jan , Zhang, Yanming , Dewald, Gordon W., Alejos, David , Luger, Selina M. , Foroni, Letizia, Patel, Bela , Melnick, Ari , Marks, David I. , Moorman, Anthony V. , Wiernik, Peter H. , Rowe, Jacob M. , Tallman, Martin S. , Goldstone, Anthony H., Litzow, Mark R. , Gu, Zhaohui , Harvey, Richard , Lazarus, Hillard M , Fielding, Adele K , Melnick, Ari , Mullighan, Charles G , Litzow, Mark R. , Pounds, Stanley B , Roberts, Kathryn G. , Cheng, Cheng , Abdel‐Wahab, Omar , Wu, Gang , Qu, Chunxu , Shi, Lei Gang , Willman, Cheryl L. , Harvey, Richard C. , Ketterling, Rhett P. , Lazarus, Hillard M. , Fielding, Adele K. , Mullighan, Charles G.

Mayo Clinic

Blood | April 25, 2021 | Volume: 138 | Issue: 11 | Pages: 948-958

10.1182/blood.2020010144 | PMID 33895809 Get It

Abstract Genomic classification has improved risk assignment of pediatric, but not adult B-lineage acute lymphoblastic leukemia (B-ALL). The international UKALLXII/ECOG-ACRIN E2993 (#NCT00002514) trial accrued 1229 adolescent/adult patients with BCR-ABL1− B-ALL (aged 14 to 65 years). Although 93% of patients achieved remission, 41% relapsed at a median of 13 months (range, 28 days to 12 years). Five-year overall survival (OS) was 42% (95% confidence interval, 39, 44). Transcriptome sequencing, gene expression profiling, cytogenetics, and fusion polymerase chain reaction enabled genomic subtyping of 282 patient samples, of which 264 were eligible for trial, accounting for 64.5% of E2993 patients. Among patients with outcome data, 29.5% with favorable outcomes (5-year OS 65% to 80%) were deemed standard risk (DUX4-rearranged [9.2%], ETV6-RUNX1/-like [2.3%], TCF3-PBX1 [6.9%], PAX5 P80R [4.1%], high-hyperdiploid [6.9%]); 50.2% had high-risk genotypes with 5-year OS of 0% to 27% (Ph-like [21.2%], KMT2A-AFF1 [12%], low-hypodiploid/near-haploid [14.3%], BCL2/MYC-rearranged [2.8%]); 20.3% had intermediate-risk genotypes with 5-year OS of 33% to 45% (PAX5alt [12.4%], ZNF384/-like [5.1%], MEF2D-rearranged [2.8%]). IKZF1 alterations occurred in 86% of Ph-like, and TP53 mutations in patients who were low-hypodiploid (54%) and BCL2/MYC-rearranged (33%) but were not independently associated with outcome. Of patients considered high risk based on presenting age and white blood cell count, 40% harbored subtype-defining genetic alterations associated with standard- or intermediate-risk outcomes. We identified distinct immunophenotypic features for DUX4-rearranged, PAX5 P80R, ZNF384-R/-like, and Ph-like genotypes. These data in a large adult B-ALL cohort treated with a non–risk-adapted approach on a single trial show the prognostic importance of genomic analyses, which may translate into future therapeutic benefits.
COVID-19 Impact on Interventional Pulmonology Training
Kalchiem‐Dekel, Or , Schwalk, Audra, Patel, Niral M. , Lin, I‐Hsin , Beattie, Jason , Husta, Bryan , Chawla, Mohit , Sachdeva, Ashutosh , Akulian, Jason , Musani, Ali I., Argento, A. Christine , Lee, Hans J. , Mullon, John J., Desai, Neeraj, Lee, Robert P. , Hsia, David W.

Mayo Clinic

ATS Scholar | April 13, 2021 | Volume: 2 | Issue: 2 | Pages: 236-248

10.34197/ats-scholar.2020-0126oc | PMID 34409418 Get It

Abstract Background The impact of the coronavirus disease (COVID-19) pandemic extends beyond the realms of patient care and healthcare resource use to include medical education; however, the repercussions of COVID-19 on the quality of training and trainee perceptions have yet to be explored. Objective The purpose of this study was to determine the degree of interventional pulmonology (IP) fellows’ involvement in the care of COVID-19 and its impact on fellows’ clinical education, procedure skills, and postgraduation employment search. Methods An internet-based survey was validated and distributed among IP fellows in North American fellowship training programs. Results Of 40 eligible fellows, 38 (95%) completed the survey. A majority of fellows (76%) reported involvement in the care of patients with COVID-19. Fellows training in the Northeast United States reported involvement in the care of a higher number of patients with COVID-19 than in other regions (median, 30 [interquartile range, 20–50] vs. 10 [5–13], respectively; P < 0.01). Fifty-two percent of fellows reported redeployment outside IP during COVID-19, mostly into intensive care units. IP procedure volume decreased by 21% during COVID-19 compared with pre–COVID-19 volume. This decrease was mainly accounted for by a reduction in bronchoscopies. A majority of fellows (82%) reported retainment of outpatient clinics during COVID-19 with the transition from face-to-face to telehealth-predominant format. Continuation of academic and research activities during COVID-19 was reported by 86% and 82% of fellows, respectively. After graduation, all fellows reported having secured employment positions. Conclusion Although IP fellows were extensively involved in the care of patients with COVID-19, most IP programs retained educational activities through the COVID-19 outbreak. The impact of the decrease in procedure volume on trainee competency would be best addressed individually within each training program. These data may assist in focusing efforts regarding the education of medical trainees during the current and future healthcare crises.
Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia
Kharfan‐Dabaja, Mohamed A. , Brissot, Éolia , Kroger, Nicolaus , Ciceri, Fabio , Deconinck, Éric , Blaise, Didier , Chevallier, Patrice , Gramatzki, Martin , Ganser, Arnold , Stelljes, Matthias , Sanz, Jaime , Nagler, Arnon , Mohty, Mohamad , Kröger, Nicolaus , Mohty, Mohamad , Kroger, Nicolaus , Ciceri, Fabio , Deconinck, Eric , Gramatzki, Martin , Ruggeri, Annalisa , Mohty, Mohamad , Blaise, Didier , Kröger, Nicolaus , Mohty, Mohamad , Labopin, Myriam , Finke, Jürgen , Edinger, Matthias , Savani, Bipin N.

Mayo Clinic

British Journal of Haematology | April 10, 2021 | Volume: 193 | Issue: 3 | Pages: 592-601

10.1111/bjh.17426 | PMID 33838047 Get It

SummaryOptimal donor choice for a second allogeneic haematopoietic cell transplant (allo‐HCT) in relapsed acute myeloid leukaemia (AML) remains unknown. We compared overall survival (OS) using registry data from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) involving 455 adults who received a second allo‐HCT from a human leucocyte antigen (HLA)‐matched unrelated (MUD) (n = 320) or a haploidentical (n = 135) donor. Eligibility criteria required adults aged ≥18 years who received a second allo‐HCT for treating AML relapse between 2005 and 2019. The primary end‐point was OS. There was no statistically significant difference in the median (interquartile range) age between the groups, MUD 46 (35–58) versus haploidentical 44 (33–53) years (P = 0·07). The median OS was not different between the MUD and the haploidentical groups (10 vs. 11 months, P = 0·57). Similarly, the 2‐year OS was 31% for the MUD and 29% for the haploidentical donor groups. The OS was worse if the procedure was performed with active AML [hazard ratio (HR) 1·42, 95% confidence interval (CI) 1·07–1·89; P = 0·02]. Conversely, a longer time from first allo‐HCT to relapse (>13·2 months) was associated with better OS (HR 0·50, 95% CI 0·37–0·69; P < 0·0001). The results of the present analysis limit the ability to recommend one donor type over another when considering a second allo‐HCT for relapsed AML. Our findings highlight that best OS is achieved when receiving the second allo‐HCT in complete remission.
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma
Tesileanu, C. Mircea S. , Bent, Martin J. van den , Sanson, Marc , Wick, Wolfgang , Clément, Paul M. , Erridge, Sara , Vogelbaum, Michael A., Nowak, Anna K. , Baurain, Jean Français, Mason, W. P., Wheeler, Helen , Gill, Sanjeev , Griffin, Matthew, Rogers, Leland , Taal, Walter , Weller, Michael , McBain, Catherine , Linde, Myra E. van , Hoogstrate, Youri , Deimling, Andreas von , Heer, Iris de , IJcken, Wilfred F. J. van , Brouwer, Rutger W. W. , Aldape, Kenneth , Jenkins, Robert B. , Dubbink, Hendrikus J. , Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G. , Gorlia, Thierry, French, Pim J. , van den Bent, Martin J , Weller, Michael , Jenkins, RB , Noushmehr, Houtan , Wick, Wolfgang , Sanson, Marc , Nowak, Anna K , Taal, Walter , von Deimling, Andreas , Hoogstrate, Youri , Dubbink, Hendrikus J , van IJcken, Wilfred F J , French, Pim J , Brandes, Alba Ariela , Chinot, Olivier , Rudà, Roberta , Sabedot, Thaís S. , Kros, Johan M. , Wesseling, Pieter , Noushmehr, Houtan

Mayo Clinic

Neuro-Oncology | April 6, 2021 | Volume: 23 | Issue: 9 | Pages: 1547-1559

10.1093/neuonc/noab088 | PMID 33914057 Get It

Abstract Background Survival in patients with IDH1/2-mutant (mt) anaplastic astrocytomas is highly variable. We have used the prospective phase 3 CATNON trial to identify molecular factors related to outcome in IDH1/2mt anaplastic astrocytoma patients. Methods The CATNON trial randomized 751 adult patients with newly diagnosed 1p/19q non-codeleted anaplastic glioma to 59.4 Gy radiotherapy +/− concurrent and/or adjuvant temozolomide. The presence of necrosis and/or microvascular proliferation was scored at central pathology review. Infinium MethylationEPIC BeadChip arrays were used for genome-wide DNA methylation analysis and the determination of copy number variations (CNV). Two DNA methylation-based tumor classifiers were used for risk stratification. Next-generation sequencing (NGS) was performed using 1 of the 2 glioma-tailored NGS panels. The primary endpoint was overall survival measured from the date of randomization. Results Full analysis (genome-wide DNA methylation and NGS) was successfully performed on 654 tumors. Of these, 432 tumors were IDH1/2mt anaplastic astrocytomas. Both epigenetic classifiers identified poor prognosis patients that partially overlapped. A predictive prognostic Cox proportional hazard model identified that independent prognostic factors for IDH1/2mt anaplastic astrocytoma patients included; age, mini-mental state examination score, treatment with concurrent and/or adjuvant temozolomide, the epigenetic classifiers, PDGFRA amplification, CDKN2A/B homozygous deletion, PI3K mutations, and total CNV load. Independent recursive partitioning analysis highlights the importance of these factors for patient prognostication. Conclusion Both clinical and molecular factors identify IDH1/2mt anaplastic astrocytoma patients with worse outcome. These results will further refine the current WHO criteria for glioma classification.
Harnessing the Chaplain’s Capacity to Identify Unmet Palliative Needs of Vulnerable Older Adults in the Emergency Department
Howard, E , Schwartz, Rachel , Feldstein, Bruce, Grudzen, Marita, Klein, Lori , Piderman, Katherine M. , Hamill Howard, Elizabeth , Schwartz, Rachel , Wang, David

Mayo Clinic

Journal of Palliative Care | April 5, 2021 | Volume: 37 | Issue: 4 | Pages: 480-485

10.1177/08258597211003359 | PMID 33818162 Get It

Objective: To explore chaplains’ ability to identify unmet palliative care (PC) needs in older emergency department (ED) patients. Methods: A palliative chaplain-fellow conducted a retrospective chart review evaluating 580 ED patients, age ≥80 using the Palliative Care and Rapid Emergency Screening (P-CaRES) tool. An emergency medicine physician and chaplain-fellow screened 10% of these charts to provide a clinical assessment. One year post-study, charts were re-examined to identify which patients received PC consultation (PCC) or died, providing an objective metric for comparing predicted needs with services received. Results: Within one year of ED presentation, 31% of the patient sub-sample received PCC; 17% died. Forty percent of deceased patients did not receive PCC. Of this 40%, chaplain screening for P-CaRES eligibility correctly identified 75% of the deceased as needing PCC. Conclusion: Establishing chaplain-led PC screenings as standard practice in the ED setting may improve end-of-life care for older patients.
Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
Privitera, Michael , Bhathal, Hari, Wong, Matthew H. , Cross, J. Helen , Wirrell, Elaine , Marsh, Eric D. , Mazurkiewicz‐Bełdzińska, Maria , Villanueva, Vicente , Checketts, Daniel, Knappertz, Volker, VanLandingham, Kevan, Wirrell, Elaine C , Cross, Helen J , Mazurkiewicz-Bełdzińska, Maria , Wong, Matthew

Mayo Clinic

Epilepsia | April 2, 2021 | Volume: 62 | Issue: 5 | Pages: 1130-1140

10.1111/epi.16878 | PMID 33797076 Get It

AbstractObjectiveTo estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data from two randomized, placebo‐controlled, Phase 3 trials, GWPCARE3 (NCT02224560) and GWPCARE4 (NCT02224690), of patients with Lennox–Gastaut syndrome.MethodsPatients received plant‐derived pharmaceutical formulation of highly purified CBD (Epidiolex, 100 mg/ml oral solution) at 10 mg/kg/day (CBD10; GWPCARE3) or 20 mg/kg/day (CBD20; both trials) or placebo for 14 weeks. Treatment started at 2.5 mg/kg/day for all groups and reached 10 mg/kg/day on Day 7 and 20 mg/kg/day (CBD20 and matching placebo only) on Day 11. Percentage change from baseline in drop seizure frequency was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated.ResultsOverall, 235 patients received CBD (CBD10 [GWPCARE3 only],n = 67; CBD20 [pooled GWPCARE3&4],n = 168) and 161 received placebo. Mean (range) age was 15.3 years (2.6–48.0). Patients had previously discontinued a median (range) of six (0–28) antiepileptic drugs (AEDs) and were currently taking a median of three (0–5) AEDs. Differences in drop seizure reduction between placebo and CBD emerged during the titration period and became nominally significant by Day 6 (p = .008) for pooled CBD treatment groups. Separation between placebo and CBD in ≥50% responder rate emerged by Day 6. Onset of the first reported AE occurred during the titration period in 45% of patients (CBD10, 46%; CBD20, 52%; placebo, 38%). In patients with AEs, resolution occurred within 4 weeks of onset in 53% of placebo and 39% of CBD patients and by end of study in 63% of placebo and 61% of CBD patients.SignificanceTreatment effect (efficacy and AEs) of CBD may occur within 1 week of starting treatment. Although AEs lasted longer for CBD than placebo, most resolved within the 14‐week period.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Venner, Christopher P. , Offner, Fritz , White, Darrell , Karlin, Lionel, Benboubker, Lotfi , Rigaudeau, Sophie , Rodon, Philippe, Voog, Éric , Suzuki, Kenshi , Zhang, Xiaoquan , Twumasi‐Ankrah, Philip, Rifkin, Robert M. , Kumar, Shaji , Richardson, Paul G. , Benboubker, Lotfi , Voog, Eric , Yoon, Sung-Soo , Suzuki, Kenshi , Shibayama, Hirohiko , Yung, Godwin , Kumar, Shaji K , Rajkumar, S Vincent , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Karlin, Lionel , Yoon, Sung‐Soo , Shibayama, Hirohiko , Yung, Godwin , Moreau, Philippe , Lonial, Sagar , Richardson, Paul Gerard Guy , Rajkumar, S. Vincent

Mayo Clinic

Blood | March 24, 2021 | Volume: 137 | Issue: 26 | Pages: 3616-3628

10.1182/blood.2020008787 | PMID 33763699 Get It

Abstract Continuous lenalidomide-dexamethasone (Rd)-based regimens are among the standards of care in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. The oral proteasome inhibitor ixazomib is suitable for continuous dosing, with predictable, manageable toxicities. In the double-blind, placebo-controlled TOURMALINE-MM2 trial, transplant-ineligible NDMM patients were randomized to ixazomib 4 mg (n = 351) or placebo (n = 354) plus Rd. After 18 cycles, dexamethasone was discontinued and treatment was continued using reduced-dose ixazomib (3 mg) and lenalidomide (10 mg) until progression/toxicity. The primary endpoint was progression-free survival (PFS). Median PFS was 35.3 vs 21.8 months with ixazomib-Rd vs placebo-Rd, respectively (hazard ratio [HR], 0.830; 95% confidence interval, 0.676-1.018; P = .073; median follow-up, 53.3 and 55.8 months). Complete (26% vs 14%; odds ratio [OR], 2.10; P &lt; .001) and ≥ very good partial response (63% vs 48%; OR, 1.87; P &lt; .001) rates were higher with ixazomib-Rd vs placebo-Rd. In a prespecified high-risk cytogenetics subgroup, median PFS was 23.8 vs 18.0 months (HR, 0.690; P = .019). Overall, treatment-emergent adverse events (TEAEs) were mostly grade 1/2. With ixazomib-Rd vs placebo-Rd, 88% vs 81% of patients experienced grade ≥3 TEAEs, 66% vs 62% serious TEAEs, and 35% vs 27% TEAEs resulting in regimen discontinuation; 8% vs 6% died on study. Addition of ixazomib to Rd was tolerable with no new safety signals and led to a clinically meaningful PFS benefit of 13.5 months. Ixazomib-Rd is a feasible option for certain patients who can benefit from an all-oral triplet combination. This trial was registered at www.clinicaltrials.gov as #NCT01850524.
Intubation Practices and Adverse Peri-intubation Events in Critically Ill Patients From 29 Countries
Russotto, Vincenzo , Laffey, John G. , Tassistro, Elena , Camporota, Luigi , Higgs, A. , Putensen, Christian , Agvald‐Öhman, Christina, Bokums, Kristaps, Brewster, David , Rossi, Emanuela , Fumagalli, Roberto , Pesenti, Antonio, Investigators, INTUBE Study, Ahmed, Hazem , Adhikari, Neill K. J. , Agrawal, Kehari, Agrawal, Nipun , Aguirre-Bermeo, Hernán , Agvald-Öhman, Christina, Ahmad, Meraj, Ajami, Samareh, Akhtar, Shazia N., Alghamdi, Adnan, Alhadi, Abdulmueti , Ali, Syed Muhammad Adnan , Ali, Mohd N., Alias, Anita, Alonso, Julio, Montenegro, Diana Alvarez, Aman, Rubina, Anstey, Matthew , Αrnaoutoglou, Eleni , Baccari, Laura, Baliga, Nishanth, Manjunath, Ramya Ballekatte, Bamane, Shrirang, Bandert, Anna , Bartholdy, Roland, Baturova, Vera , Bellissima, Agrippino , Belsky, Vladislav, Bendre, Prashant, Benini, Annalisa, Besset, Sébastien , Bhattacharyya, Mahuya , Bielański, Piotr, Bigatello, Luca M., Boissier, Florence , Bonney, Iwona, Bowen, David , Boyer, Alexandre, Broman, Lina , Bruel, Cédric , Brunin, Yannick, Bugedo, Guillermo , Calamai, Italo , Campos, Patricia , Canavosio, Federico Giovanni , Cascella, Marco , Catorze, Nuno , Champigneulle, Benoît , Chandwani, Juhi, Chaurasia, Satish, Chawla, Rajesh , Chawla, Aakanksha, Cheetham, Olivia, Chemouni, Frank , Kiok, Lee Chew, Chimunda, Timothy , Chiu, Ching‐Tang , Chiumiento, Fernando, Chudeau, Nicolas , Colica, Sandra, Colin, Gwenhaël , Constantin, Jean‐Michel , Contou, Damien , Costa, Paulo F., Costa, Vasco , Cracchiolo, Andrea, Crone, Petra, Cunha, Rui Pedro, Radivojević, Renata Curić , Dash, Sampat, Pascale, Gennaro De , Torre, Valentina Della, Caprio, Barbara Di, Dimitropoulou, Aikaterini, Edmunds, Christopher , El-Fellah, Nadia, Elhadi, Ahmed , Escudero-Acha, P. , Espinoza, Missael, Esposito, Clelia, Fabretti, Fabrizio, Fein, Daniel , Ferluga, Massimo, Ferré, Alexis , Ferrier, Janet, Flaksa, Marek, Flores, Fernando , Gonzalez, Jesus Flores, Fuentes, Xavier Fonseca , Francis, Roland C. E. , Franco, Daniela G., Franczyk, Pawel, Furman, Mikhail, Gałkin, Piotr, Aguilera, Maria F. García, Garofalo, Eugenio , Gatward, Jonathan, Ghula, Mohamed , Giacomucci, Angelo , Giovannini, Ilaria , Gnanadurai, Kingsly Robert, Godet, Thomas, Fernandez, Gemma Goma , González, María del Carmen Martín, González, Daira, Gopalakrishna, Kadarapura Nanjundaiah , Gottesman, Eric , Gros, Alexandre, Gupta, Manish , Gupta, Kulbhusahn, Hamid, Tarikul , Hamzaoui, Olfa, Hannesdottir, Katrin, Hasan, Shahnaz, Hossain, Mozaffer, Hossein, Sazzad, Hraiech, Sami , Hypes, Cameron, Alkhumsi, Soad Imhmed R., Islam, Motiul, Ismail, Muhamad A., Ivančan, Višnja , Jacquier, Sophie , Jagiasi, Bharat, Jain, Nikhilesh , Jamaluddin, Muhamad Fadhil Hadi, Jeswani, Deepak , Jeswani, Deepti, Jha, Simant , Jones, Benjamin , Jozwiak, Mathieu , Jumić, Aleksandra, Kamp, Oliver , Karametos, Ilias, Karelov, Alexey, Kaufman, David A. , Kaushik, Shuchi, Kesavarapu, Subba R., Khaled, Ala , Khalidah, Hapiz, Khunteta, Sudhir , Kindgen‐Milles, Detlef , Korula, Sara , Kothekar, Amol , Koul, Salman S., Krog, Ditte, Kuellmar, Mira, Kuragayala, Swarna Deepak , Kyparissi, Aikaterini, Labarca, Gonzalo , Lalwani, Jaya, Landaverde, Antonio, Lehr, Andrew , Leonor, Tiago, Licciardi, A, Nava, Claudia L. Lopez, Gallardo, Luis R. Loza, Lungu, Ramona , Luzi, Annalisa, Ma, Wuhua , Μakris, Alexandros , Maheshwarappa, Harish Mallapura , Maraffi, Tommaso , Marcelli, Maria Elena, Mariano, Karim, Marin, Nathalie, Martin, Maëlle, Gonzalez, Mayra Martinez, Matas, Marijana , Matos, Dubier, Maugeri, Jessica Giuseppina , Mazlan, Mohd Zulfakar , Meersch, Melanie , Meher, Ranjan, Mehesry, Tasneem H., Meirik, Maria, Dessap, Armand Mekontso , Mensah, Kwabena , Mercier, Emmanuelle, Midya, Abhirup, Mihaljević, Slobodan , Mirouse, Adrien , Mishra, Prasanna K. , Mistry, Ravi , Moguš, Mate, Nordin, Norbaniza Mohd, Samat, Noryani Mohd, Montini, Luca, Moro, Valeria, Tutillo, Diego Morocho , Mrinal, Sircar, Mudyna, Wojciech, Munta, Kartik, Munusamy, Satheesh , Musso, Stefania, Muttini, Stefano , Irtiza, Ismail Nahla, Nakou, Evi, Narkhede, Amit , Nates, Joseph, Nespoli, M, Nespoli, Francesca, Nikitenko, Artem, Nogueira, Carla, O'Grady, Ross, Odeyemi, Yewande , Ohlsson, Annika , Orsello, Alberto, Palaniswamy, Vijayanand , Palma, Daniela Maria , Palmese, Salvatore , Leal, Jesus N. Pantoja, Papandreou, E., Papanikolaou, Metaxia, Patel, Mayur , Pavlek, Mario , Pedrotti, Niccolò , Hwa, Ngu Pei, Pelagalli, Lorella, Ruiz, Miryam Pérez, Persson, Elin, Petsiou, Athanasia, Philippard, Francois, Piegat, Mariusz, Pili‐Floury, Sébastien, Pinto, Márcia , Piton, Gaël , Plantefève, Gaëtan , Pouplet, Caroline, Pouriki, Sofia, Pradella, Andrea , Prashant, Kumar , Quayle, Alice, Rahmani, Lua S. , Randall, Ian , Ray, Banambar , Reza, Syed T., Ricard, Jean Damien, Riva, Ivano, Rona, Roberto , Rosell, Jon, Rowley, Rebecca, Rumschuessel, Kay, Rundo, Annalisa, Russo, Pierpaolo, Sahu, Samir, Salmon-Gandonnière, Charlotte, Roman, Nandyelly San Juan, Sandefur, Benjamin J. , Santoro, Lida, Sanyal, Rhik, Saravanabavan, Lakshmikanthcharan , Shah, Bhagyesh, Shah, Mehul , Shin, Ming-Hann, Simpson, Shannon, Sinah, Ayush, Singh, D. K., Singh, Nitesh , Singh, Lalit, Skowronski, Lukasz , Sosa, Miguel A. Gama , Spadaro, Savino , Spångfors, Martin , Sperber, Jesper , Spina, Rosario, Srivastava, Anand , Steel, Andrew, Suárez-de-la-Rica, Alejandro , Kumar, Singh Sujeet, Sundrani, Omprakash, Sunil, Nilu, Suparna, Bharadwaj, Surath, Manimala R., Syed, Yadullah, Sztrymf, Benjamin , Tarantino, Stefano, Tileli, Maria, Castro, Hugo Arturo Tirapé , Toledo-Salinas, Otoniel , Tramarin, Jacopo, Tsiftsis, D , Tucić, Iva , León, Jose A. Tutillo, Tutino, Lorenzo, Tyagi, Vijay, Vagdatli, Kyriaki, Varkey, Sneha, Vera, Magdalena , Seth, Magnus Von, Wahlström, C.-G., Ismail, Wan Nasrudin Wan, Winiszewski, Hadrien , Wu, Lun , Zani, Gianluca , Zarka, Jonathan , Zhao, Dawn, Zlotnik, Diane , Bauer, Philippe, Laffey, John G , Labarca, Gonzalo , Alhadi, Abdulmueti , Myatra, Sheila Nainan , Antolini, Laura , Bauer, Philippe R. , Lascarrou, Jean-Baptiste , Szuldrzynski, Konstanty S. , Pelosi, Paolo , Sorbello, Massimiliano , Greif, Robert , Chalkias, Athanasios F. , Pesenti, Antonio, Foti, Giuseppe , Bellani, Giacomo , Investigators, INTUBE Study, Agvald-Öhman, Christina, Ahmad, Meraj, Almekhlafi, Ghaleb A. , Aragão, Irene , Azoulay, Élie , Basto, Marta Lima , Besset, Sebastien, Boni, Elisa, Brazzi, Luca , Broman, Lina, Browne, Alexander, Cappellini, Iacopo , Chao, Anne , Chien, Jung‐Yien , Chou, Nai‐Kuan , Cortegiani, Andrea , Costamagna, Andrea , Cotoia, Antonella , Cracchiolo, Andrea N., Das, Amit, Rosa, Silvia De , Sorbo, Lorenzo Del , Fenza, Raffaele Di , Giacinto, Ida Di , Dudda, Marcel , Ehrentraut, Stefan , Elhadi, Muhammed , Fernandes, Marco, Flores, Fernando, Frat, Jean-Pierre , Fusari, Maurizio , Moraes, Alice Gallo de , Gammaldi, Renato , Gaszynski, Tomasz M , Godet, Thomas , Goffi, Alberto , González-Castro, A. , Guervilly, Christophe , Guitton, Christophe , Huang, Chun‐Kai , Jankowski, Miłosz , Jones, Laura, Karelov, Alexey, Katsoulis, P. , Kaye, Callum T. , Khalidah, Hapiz, Khan, Akram , Ku, Shih‐Chi , Kuo, Lu-Cheng , Lalwani, Jaya, Laserna, Andrés , Lee, Chien‐Chang , Legriel, Stéphane , Li, Yongxing , Licciardi, Anna Lisa, Litton, Edward , Ломиворотов, В. В. , Longhini, Federico , Магомедов, М. А. , Геннадьевна, Марова Надежда , Maseda, Emilio , Mastroianni, Fiore , Michálek, Pavel , Mishra, Prasanna, Mistry, Ravi, Montini, Luca , Montrucchio, Giorgia Giuseppina , Mosier, Jarrod , Mudyna, Wojciech, Müller, Grégoire , Munta, Kartik, Musso, Stefania, Nakou, Evi, Nates, Joseph L. , Nogueira, Carla, Leal, Jesús Nicolás Pantoja, Papandreou, Eleni, Parotto, Matteo , Persson, Elin, Pezzi, Angelo , Philip, Sam, Pinciroli, Riccardo , Pinto, Marcia, Pouplet, Caroline, Regli, Adrian , Roca, Oriol , Rosell, Jon, Ruan, Sheng‐Yuan , Sahu, Samir, Sales, Gabriele , Roman, Nandyelly San Juan, Sánchez‐Hurtado, Luis Alejandro , Santafe, Manel, Sanyal, Rhik, Shah, Bhagyesh, Silva, Monica, Simpson, Shannon, Singh, Atul Kumar , Singh, Lalit, Sosa, Miguel A., Srivastava, Anand, Szakmány, Tamás , Tabah, Alexis , León, José Andrés Tutillo , Wahlstrom, Carl, Hassan, Wan Mohd Nazaruddin Wan , Wang, Kuo‐Chuan , Wu, Jiayan , Yeh, Yu‐Chang , Young, Paul J.

Mayo Clinic

JAMA | March 23, 2021 | Volume: 325 | Issue: 12 | Pages: 1164

10.1001/jama.2021.1727 | PMID 33755076 Get It

Rectosigmoid resection by gynecologic oncologists versus colorectal surgeons: as long as it catches the mouse, does the color of the cat matter?
Chang, Suk‐Joon , Fotopoulou, Christina , Bristow, Robert E. , Dennis, S. , Cliby, William A. , Chi, Dennis S , Cliby, William A

Mayo Clinic

Journal of Gynecologic Oncology | March 23, 2021 | Volume: 32 | Issue: 3 | Pages: No page available

10.3802/jgo.2021.32.e51 | PMID 33825361 Get It